Literature DB >> 23280795

Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas.

Hagen Kunte1, Markus A Busch, Katrin Trostdorf, Bernd Vollnberg, Lutz Harms, Rupal I Mehta, Rudolf J Castellani, Pitchaiah Mandava, Thomas A Kent, J Marc Simard.   

Abstract

OBJECTIVE: Disability or death occurs more frequently in patients with hemorrhagic transformation (HT) after ischemic stroke. In rat models of stroke, sulfonylurea (SU) drugs such as glibenclamide (adopted US name, glyburide) confer protection against swelling and HT through actions on the novel SUR1-regulated NC(Ca-ATP) channel. Here, we sought to determine whether the use of SU drugs in patients with diabetes mellitus (DM) presenting with acute ischemic stroke might influence the incidence of HT.
METHODS: We retrospectively analyzed data on 220 patients with DM who presented with acute ischemic stroke, 43 of whom were managed with and continued to receive SU drugs, and 177 of whom were managed without (controls).
RESULTS: During a median length of stay in hospital of 11 days, 20 control patients (11%) experienced symptomatic HT (sHT), whereas no patient in the SU group experienced sHT (p = 0.016). No patient in the SU group died, compared to 18 (10%) in the control group (p = 0.027). Similarly favorable outcomes were observed after matching for baseline imbalances and excluding outliers. In support of the proposed mechanism, we present a case of sHT in which an analysis of brain tissues obtained intraoperatively showed prominent upregulation of SUR1, the target of SU drugs, in microvessels and neurons.
INTERPRETATION: We conclude that, in diabetic patients with acute ischemic stroke, prior and continued use of SU drugs is associated with reduced sHT compared to those whose treatment regimen does not include SU drugs.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280795      PMCID: PMC3539226          DOI: 10.1002/ana.23680

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  The role of ATP-sensitive potassium channels in neutrophil migration and plasma exudation.

Authors:  José Eduardo Da Silva-Santos; Maria Cláudia Santos-Silva; Fernando de Queiroz Cunha; Jamil Assreuy
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

2.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

3.  Letter by Simard et al regarding article, "Sulfonylurea use before stroke does not influence outcome".

Authors:  J Marc Simard; Thomas A Kent; Hagen Kunte
Journal:  Stroke       Date:  2011-05-19       Impact factor: 7.914

4.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

Review 5.  Intracranial hemorrhage associated with revascularization therapies.

Authors:  Pooja Khatri; Lawrence R Wechsler; Joseph P Broderick
Journal:  Stroke       Date:  2007-01-18       Impact factor: 7.914

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

8.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

9.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

10.  Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke.

Authors:  J Marc Simard; Mingkui Chen; Kirill V Tarasov; Sergei Bhatta; Svetlana Ivanova; Ludmila Melnitchenko; Natalya Tsymbalyuk; G Alexander West; Volodymyr Gerzanich
Journal:  Nat Med       Date:  2006-03-19       Impact factor: 53.440

View more
  42 in total

1.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

2.  Treatment of malignant brain edema and increased intracranial pressure after stroke.

Authors:  Michael E Brogan; Edward M Manno
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

3.  Sur1-Trpm4 Cation Channel Expression in Human Cerebral Infarcts.

Authors:  Rupal I Mehta; Cigdem Tosun; Svetlana Ivanova; Natalia Tsymbalyuk; Bolanle M Famakin; Min Seong Kwon; Rudy J Castellani; Volodymyr Gerzanich; J Marc Simard
Journal:  J Neuropathol Exp Neurol       Date:  2015-08       Impact factor: 3.685

Review 4.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 5.  Using human experience to identify drug repurposing opportunities: theory and practice.

Authors:  D Cavalla
Journal:  Br J Clin Pharmacol       Date:  2019-02-03       Impact factor: 4.335

6.  Exploratory analysis of glyburide as a novel therapy for preventing brain swelling.

Authors:  Kevin N Sheth; W Taylor Kimberly; Jordan J Elm; Thomas A Kent; Albert J Yoo; Götz Thomalla; Bruce Campbell; Geoffrey A Donnan; Stephen M Davis; Gregory W Albers; Sven Jacobson; Gregory del Zoppo; J Marc Simard; Barney J Stern; Pitchaiah Mandava
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

7.  Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.

Authors:  Yi Zhang; Md Nasrul Hoda; Xuan Zheng; Weiguo Li; Pengcheng Luo; Krishna Rao Maddipati; Tsugio Seki; Adviye Ergul; Mong-Heng Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-02       Impact factor: 3.619

8.  Explicit consideration of baseline factors to assess recombinant tissue-type plasminogen activator response with respect to race and sex.

Authors:  Pitchaiah Mandava; Santosh B Murthy; Melody Munoz; Dawn McGuire; Roger P Simon; Andrei V Alexandrov; Karen C Albright; Amelia K Boehme; Sheryl Martin-Schild; Sharyl Martini; Thomas A Kent
Journal:  Stroke       Date:  2013-05-14       Impact factor: 7.914

9.  Edaravone offers neuroprotection for acute diabetic stroke patients.

Authors:  J Zheng; X Chen
Journal:  Ir J Med Sci       Date:  2015-11-23       Impact factor: 1.568

10.  Pilot study of intravenous glyburide in patients with a large ischemic stroke.

Authors:  Kevin N Sheth; W Taylor Kimberly; Jordan J Elm; Thomas A Kent; Pitchaiah Mandava; Albert J Yoo; Götz Thomalla; Bruce Campbell; Geoffrey A Donnan; Stephen M Davis; Gregory W Albers; Sven Jacobson; J Marc Simard; Barney J Stern
Journal:  Stroke       Date:  2013-11-05       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.